A randomised, double-blinded trial to assess the effect of oclacitinib and prednisolone on intradermal allergen and prick tests in dogs with atopic dermatitis

CONCLUSIONS AND CLINICAL RELEVANCE: The use of oclacitinib 0.4-0.58 mg/kg twice daily for 14 days does not interfere with IDT results in dogs with cAD. However, oclacitinib may reduce PT reactivity. The use of prednisolone 0.37-0.65 mg/kg twice daily results in a reduction in both IDT and PT results.PMID:37770410 | DOI:10.1111/vde.13209

Source: Veterinary Dermatology - September 28, 2023 Category: Veterinary Research Authors: Let ícia Talita Baretta Victor do Esp írito Santo Cunha Cristiane Deon Figueiredo Daniel Guimar ães Gerardi Source Type: research